- Scheme Category:
- Equity Scheme >
- Sectoral/Thematic Funds
NAV: ₹ ↓ -0.07%
NAV chart
SMA (Simple Moving Average)
- 50 SMA
- 100 SMA
- 200 SMA
- 400 SMA
Returns
CAGR returns till date
CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option and its peers as on 16 June, 2026| Name | YTD | 1D | 1W | 1M | 3M | 1Y | 3Y | 5Y | 7Y | 10Y |
|---|---|---|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option | 5.67% | -0.07% | -0.09% | -1.58% | 7.73% | 4.79% | 21.61% | 13.5% | 22.17% | 16.21% |
| SBI CONSUMPTION OPPORTUNITIES FUND - DIRECT PLAN - GROWTH | -7.04% | 0.14% | 2.46% | -0.4% | 5.23% | -6.27% | 8.6% | 14.02% | 15.37% | 14.89% |
| SBI ESG Exclusionary Strategy Fund - Direct Plan -Growth | -4.4% | 0.46% | 3.16% | 3.43% | 6.82% | -0.62% | 11.11% | 10.73% | 12.59% | 12.73% |
| SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH | 12.03% | -0.55% | 0.9% | 1.87% | 12.8% | 11.21% | 25.19% | 16.73% | 24.52% | 14.54% |
| SBI INFRASTRUCTURE FUND - DIRECT PLAN - GROWTH | 2.67% | 0.72% | 1.75% | 0.68% | 12.08% | 3.47% | 18.27% | 19.3% | 18.87% | 16.22% |
| SBI PSU Fund - DIRECT PLAN - GROWTH | 2.88% | -0.15% | 0.43% | -0.64% | 2.03% | 9.51% | 29.34% | 24.15% | 19.73% | 15.91% |
Discrete returns (yearly)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns | -9.42% | 8.09% | 4.71% | 2.97% | 68.53% | 23.84% | -9.16% | 41.33% | 35.46% | -2.94% |
Discrete returns (monthly)
| Month | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns | -1.41% | -2.52% | 2.24% | 0.9% | -1.24% | -4.66% | 5.31% | -4.85% | 6.03% | 2.37% |
Returns from spefic dates
| Description | CAGR returns from 18 Oct 2021 (Nifty 50 2021 high) | CAGR returns from 26 Sep 2024 (Nifty 50 2024 high) |
|---|---|---|
| Returns | 13.46% | 2.57% |
Portfolio
Asset allocation
| Equity | Debt | Realestate | Commodities | Cash & Equivalents |
|---|---|---|---|---|
| 99.45% | 0.00% (Arbitrage: 0.00%) | 0.00% | 0.00% | 0.55% |
Equity
| Name | Symbol / ISIN | Sector | Weight % |
|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA (INE044A01036) | Pharmaceuticals & Biotechnology | 13.92% |
| Lupin Limited | LUPIN (INE326A01037) | Pharmaceuticals & Biotechnology | 8.45% |
| Divi's Laboratories Limited | DIVISLAB (INE361B01024) | Pharmaceuticals & Biotechnology | 6.41% |
| Dr. Reddy's Laboratories Limited | DRREDDY (INE089A01031) | Pharmaceuticals & Biotechnology | 5.96% |
| Cipla Limited | CIPLA (INE059A01026) | Pharmaceuticals & Biotechnology | 5.42% |
| Apollo Hospitals Enterprise Limited | APOLLOHOSP (INE437A01024) | Healthcare Services | 5.15% |
| MedPlus Health Services Limited | MEDPLUS (INE804L01022) | Retailing | 3.86% |
| Ajanta Pharma Limited | AJANTPHARM (INE031B01049) | Pharmaceuticals & Biotechnology | 3.36% |
| Max Healthcare Institute Limited | MAXHEALTH (INE027H01010) | Healthcare Services | 3.24% |
| Vijaya Diagnostic Centre Limited | VIJAYA (INE043W01024) | Healthcare Services | 3.15% |
| Sai Life Sciences Limited | SAILIFE (INE570L01029) | Pharmaceuticals & Biotechnology | 3.15% |
| Mankind Pharma Limited | MANKIND (INE634S01028) | Pharmaceuticals & Biotechnology | 2.87% |
| Aurobindo Pharma Limited | AUROPHARMA (INE406A01037) | Pharmaceuticals & Biotechnology | 2.81% |
| IPCA Laboratories Limited | IPCALAB (INE571A01038) | Pharmaceuticals & Biotechnology | 2.77% |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO (INE159A01016) | Pharmaceuticals & Biotechnology | 2.64% |
| Abbott India Limited | ABBOTINDIA (INE358A01014) | Pharmaceuticals & Biotechnology | 2.43% |
| Alkem Laboratories Limited | ALKEM (INE540L01014) | Pharmaceuticals & Biotechnology | 2.17% |
| JB Chemicals & Pharmaceuticals Limited | JBCHEPHARM (INE572A01036) | Pharmaceuticals & Biotechnology | 2.09% |
| Dr. Lal Path Labs Limited | LALPATHLAB (INE600L01024) | Healthcare Services | 2.02% |
| Thyrocare Technologies Limited | THYROCARE (INE594H01019) | Healthcare Services | 1.94% |
| Pfizer Limited | PFIZER (INE182A01018) | Pharmaceuticals & Biotechnology | 1.90% |
| Gland Pharma Limited | GLAND (INE068V01023) | Pharmaceuticals & Biotechnology | 1.72% |
| Narayana Hrudayalaya Limited | NH (INE410P01011) | Healthcare Services | 1.67% |
| Emcure Pharmaceuticals Limited | EMCURE (INE168P01015) | Pharmaceuticals & Biotechnology | 1.51% |
| Sanofi Consumer Healthcare India Limited | SANOFICONR (INE0UOS01011) | Pharmaceuticals & Biotechnology | 1.16% |
| Suraksha Diagnostic Limited | SURAKSHA (INE877V01027) | Healthcare Services | 1.12% |
| Fortis Healthcare Limited | FORTIS (INE061F01013) | Healthcare Services | 1.11% |
| Sanofi India Limited | SANOFI (INE058A01010) | Pharmaceuticals & Biotechnology | 0.94% |
| Syngene International Limited | SYNGENE (INE398R01022) | Healthcare Services | 0.93% |
| Akums Drugs and Pharmaceuticals Limited | AKUMS (INE09XN01023) | Pharmaceuticals & Biotechnology | 0.89% |
| Anthem Biosciences Limited | ANTHEM (INE0CZ201020) | Pharmaceuticals & Biotechnology | 0.88% |
| Biocon Limited | BIOCON (INE376G01013) | Pharmaceuticals & Biotechnology | 0.67% |
| AstraZeneca Pharma India Limited | ASTRAZEN (INE203A01020) | Pharmaceuticals & Biotechnology | 0.62% |
| Indoco Remedies Limited | INDOCO (INE873D01024) | Pharmaceuticals & Biotechnology | 0.38% |
| Concord Biotech Limited | CONCORDBIO (INE338H01029) | Pharmaceuticals & Biotechnology | 0.14% |
Portfolio data is as on date 31 March, 2026
NAV history
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - 30 days NAV (Net asset value) history
| Date | NAV | % change |
|---|---|---|
| 16 June, 2026 | 601.7777 | -0.07% |
| 15 June, 2026 | 602.1912 | -0.42% |
| 12 June, 2026 | 604.7016 | 0.5% |
| 11 June, 2026 | 601.6791 | 0.21% |
| 10 June, 2026 | 600.4294 | -0.31% |
| 9 June, 2026 | 602.3193 | 0.56% |
| 8 June, 2026 | 598.9374 | -0.04% |
| 5 June, 2026 | 599.1954 | 0.53% |
| 4 June, 2026 | 596.0213 | 0.11% |
| 3 June, 2026 | 595.3609 | 0.35% |
| 2 June, 2026 | 593.2803 | -0.07% |
| 1 June, 2026 | 593.7091 | -0.8% |
| 29 May, 2026 | 598.5008 | -1.2% |
| 27 May, 2026 | 605.7562 | -0.04% |
| 26 May, 2026 | 606.0050 | -0.33% |
| 25 May, 2026 | 608.0001 | 0.16% |
| 22 May, 2026 | 607.0458 | -1.52% |
| 21 May, 2026 | 616.3936 | 0.42% |
| 20 May, 2026 | 613.8400 | -0.3% |
| 19 May, 2026 | 615.6743 | 0.42% |
| 18 May, 2026 | 613.0786 | 0.26% |
| 15 May, 2026 | 611.4619 | 0.42% |
| 14 May, 2026 | 608.8834 | 2.03% |
| 13 May, 2026 | 596.7510 | 0.23% |
| 12 May, 2026 | 595.4100 | -1.46% |
| 11 May, 2026 | 604.2489 | 0.14% |
| 8 May, 2026 | 603.3925 | 0.28% |
| 7 May, 2026 | 601.7027 | 0.37% |
| 6 May, 2026 | 599.4765 | 2.2% |
| 5 May, 2026 | 586.5475 |
FAQ (Frequently asked questions)
What is latest/current NAV/price of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The latest NAV of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is 601.7777 as on 16 June, 2026.What are YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 5.67% as on 16 June, 2026.What are 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 4.79% as on 16 June, 2026.What are 3 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 3 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 21.61% as on 16 June, 2026.What are 5 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 5 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 13.5% as on 16 June, 2026.What are 10 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 10 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 13.5% as on 16 June, 2026.